Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: Biologic metastasis or procedural artifact?

Sentinel lymph node (SLN) biopsy is a new standard of care for patients with breast carcinoma, and allows enhanced pathologic analysis with serial sections and immunohistochemical (IHC) staining for cytokeratins to be performed on a routine basis. However, the significance of SLN micrometastases det...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2004-03, Vol.100 (5), p.929-934
Hauptverfasser: MOORE, Katrina H, THALER, Howard T, TAN, Lee K, BORGEN, Patrick I, CODY, Hiram S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 934
container_issue 5
container_start_page 929
container_title Cancer
container_volume 100
creator MOORE, Katrina H
THALER, Howard T
TAN, Lee K
BORGEN, Patrick I
CODY, Hiram S
description Sentinel lymph node (SLN) biopsy is a new standard of care for patients with breast carcinoma, and allows enhanced pathologic analysis with serial sections and immunohistochemical (IHC) staining for cytokeratins to be performed on a routine basis. However, the significance of SLN micrometastases detected only by IHC is uncertain. Are these tumor cells truly markers of metastatic potential, or simply evidence of passive displacement by preoperative instrumentation of the tumor site? Here we evaluate whether the pattern of SLN metastasis in breast carcinoma is related to the degree of manipulation at biopsy before surgery, independently of other known predictors. Among 4016 consecutive eligible patients with breast carcinoma registered in a prospective SLN database at Memorial Sloan Kettering Cancer Center, we noted patient/tumor characteristics, pathologic status of the SLN (negative, positive by hematoxylin and eosin [H&E], or positive only on IHC), and method of previous biopsy (none, fine-needle aspiration biopsy [FNAB], core needle biopsy, or surgical biopsy). Multivariate analysis showed that the likelihood of an H&E-positive SLN was significantly associated with lymphovascular invasion, tumor size, tumor type, and tumor location, but not with the method of biopsy. In contrast, the likelihood of finding an SLN positive only on IHC was unassociated with any of the four variables above, but was significantly associated with the method of biopsy. After no previous biopsy, FNAB, core needle biopsy, or surgical biopsy, IHC-positive SLN were present in 1.2%, 3.0%, 3.8%, and 4.6% of patients, respectively (P = 0.002). These data suggest that the frequency of IHC-positive SLN in patients with breast carcinoma 1) is unrelated to conventional predictors of lymph node positivity, 2) is increased after instrumentation of the tumor site, and 3) is increased approximately proportionate to the degree of manipulation. A proportion of IHC-positive SLN were present before biopsy and therefore less likely to be artifactual.
doi_str_mv 10.1002/cncr.20035
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71677233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19920524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c303t-8b70fb9fd3b3c7ce4fe863490a10697c4307eed75c40628a3ed095aa67f989ba3</originalsourceid><addsrcrecordid>eNqFkcuK1UAQhhtRnDOjGx9AeqOLgYzVl6TTbgYdvAwMuFFwFyqdimlJp4_dHeQ8iO9rjnNglq6Kor76qeJj7IWAKwEg37jFpSsJoOpHbCfAmgqElo_ZDgDaqtbq-xk7z_nn1hpZq6fsTGjbKt2aHftzG8K6xMnnEt1EwTuc5wMfqJArNPCyhpi4o3nO3C-8TMQzLcUvNPP5EPYTX-JAmceR77H4bZT5b18m3ifCXLjD5PwSA77l732c4w_veKCyjTD7bS3xfYqOhjXhzDEVP6Ir18_YkxHnTM9P9YJ9-_jh683n6u7Lp9ubd3eVU6BK1fYGxt6Og-qVM470SG2jtAUU0FjjtAJDNJjaaWhki4oGsDViY0bb2h7VBXt9n7sd8WulXLrg8_FZXCiuuTOiMUYq9V9QWCuhlnoDL-9Bl2LOicZun3zAdOgEdEdb3dFW98_WBr88pa59oOEBPenZgFcnAPMmZky4OJ8fuFq3GrRUfwHaeaEW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19920524</pqid></control><display><type>article</type><title>Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: Biologic metastasis or procedural artifact?</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>MOORE, Katrina H ; THALER, Howard T ; TAN, Lee K ; BORGEN, Patrick I ; CODY, Hiram S</creator><creatorcontrib>MOORE, Katrina H ; THALER, Howard T ; TAN, Lee K ; BORGEN, Patrick I ; CODY, Hiram S</creatorcontrib><description>Sentinel lymph node (SLN) biopsy is a new standard of care for patients with breast carcinoma, and allows enhanced pathologic analysis with serial sections and immunohistochemical (IHC) staining for cytokeratins to be performed on a routine basis. However, the significance of SLN micrometastases detected only by IHC is uncertain. Are these tumor cells truly markers of metastatic potential, or simply evidence of passive displacement by preoperative instrumentation of the tumor site? Here we evaluate whether the pattern of SLN metastasis in breast carcinoma is related to the degree of manipulation at biopsy before surgery, independently of other known predictors. Among 4016 consecutive eligible patients with breast carcinoma registered in a prospective SLN database at Memorial Sloan Kettering Cancer Center, we noted patient/tumor characteristics, pathologic status of the SLN (negative, positive by hematoxylin and eosin [H&amp;E], or positive only on IHC), and method of previous biopsy (none, fine-needle aspiration biopsy [FNAB], core needle biopsy, or surgical biopsy). Multivariate analysis showed that the likelihood of an H&amp;E-positive SLN was significantly associated with lymphovascular invasion, tumor size, tumor type, and tumor location, but not with the method of biopsy. In contrast, the likelihood of finding an SLN positive only on IHC was unassociated with any of the four variables above, but was significantly associated with the method of biopsy. After no previous biopsy, FNAB, core needle biopsy, or surgical biopsy, IHC-positive SLN were present in 1.2%, 3.0%, 3.8%, and 4.6% of patients, respectively (P = 0.002). These data suggest that the frequency of IHC-positive SLN in patients with breast carcinoma 1) is unrelated to conventional predictors of lymph node positivity, 2) is increased after instrumentation of the tumor site, and 3) is increased approximately proportionate to the degree of manipulation. A proportion of IHC-positive SLN were present before biopsy and therefore less likely to be artifactual.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.20035</identifier><identifier>PMID: 14983487</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York, NY: Wiley-Liss</publisher><subject>Adult ; Aged ; Analysis of Variance ; Biological and medical sciences ; Biopsy, Needle ; Breast Neoplasms - pathology ; Carcinoma - pathology ; Carcinoma - secondary ; Female ; Humans ; Immunohistochemistry ; Logistic Models ; Lymph Nodes - pathology ; Lymphatic Metastasis ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Neoplasm Invasiveness - pathology ; Neoplasm Staging ; Probability ; Prognosis ; Prospective Studies ; Registries ; Sensitivity and Specificity ; Sentinel Lymph Node Biopsy ; Tumors</subject><ispartof>Cancer, 2004-03, Vol.100 (5), p.929-934</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 American Cancer Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c303t-8b70fb9fd3b3c7ce4fe863490a10697c4307eed75c40628a3ed095aa67f989ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15484042$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14983487$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MOORE, Katrina H</creatorcontrib><creatorcontrib>THALER, Howard T</creatorcontrib><creatorcontrib>TAN, Lee K</creatorcontrib><creatorcontrib>BORGEN, Patrick I</creatorcontrib><creatorcontrib>CODY, Hiram S</creatorcontrib><title>Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: Biologic metastasis or procedural artifact?</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Sentinel lymph node (SLN) biopsy is a new standard of care for patients with breast carcinoma, and allows enhanced pathologic analysis with serial sections and immunohistochemical (IHC) staining for cytokeratins to be performed on a routine basis. However, the significance of SLN micrometastases detected only by IHC is uncertain. Are these tumor cells truly markers of metastatic potential, or simply evidence of passive displacement by preoperative instrumentation of the tumor site? Here we evaluate whether the pattern of SLN metastasis in breast carcinoma is related to the degree of manipulation at biopsy before surgery, independently of other known predictors. Among 4016 consecutive eligible patients with breast carcinoma registered in a prospective SLN database at Memorial Sloan Kettering Cancer Center, we noted patient/tumor characteristics, pathologic status of the SLN (negative, positive by hematoxylin and eosin [H&amp;E], or positive only on IHC), and method of previous biopsy (none, fine-needle aspiration biopsy [FNAB], core needle biopsy, or surgical biopsy). Multivariate analysis showed that the likelihood of an H&amp;E-positive SLN was significantly associated with lymphovascular invasion, tumor size, tumor type, and tumor location, but not with the method of biopsy. In contrast, the likelihood of finding an SLN positive only on IHC was unassociated with any of the four variables above, but was significantly associated with the method of biopsy. After no previous biopsy, FNAB, core needle biopsy, or surgical biopsy, IHC-positive SLN were present in 1.2%, 3.0%, 3.8%, and 4.6% of patients, respectively (P = 0.002). These data suggest that the frequency of IHC-positive SLN in patients with breast carcinoma 1) is unrelated to conventional predictors of lymph node positivity, 2) is increased after instrumentation of the tumor site, and 3) is increased approximately proportionate to the degree of manipulation. A proportion of IHC-positive SLN were present before biopsy and therefore less likely to be artifactual.</description><subject>Adult</subject><subject>Aged</subject><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Biopsy, Needle</subject><subject>Breast Neoplasms - pathology</subject><subject>Carcinoma - pathology</subject><subject>Carcinoma - secondary</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Logistic Models</subject><subject>Lymph Nodes - pathology</subject><subject>Lymphatic Metastasis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Invasiveness - pathology</subject><subject>Neoplasm Staging</subject><subject>Probability</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Registries</subject><subject>Sensitivity and Specificity</subject><subject>Sentinel Lymph Node Biopsy</subject><subject>Tumors</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcuK1UAQhhtRnDOjGx9AeqOLgYzVl6TTbgYdvAwMuFFwFyqdimlJp4_dHeQ8iO9rjnNglq6Kor76qeJj7IWAKwEg37jFpSsJoOpHbCfAmgqElo_ZDgDaqtbq-xk7z_nn1hpZq6fsTGjbKt2aHftzG8K6xMnnEt1EwTuc5wMfqJArNPCyhpi4o3nO3C-8TMQzLcUvNPP5EPYTX-JAmceR77H4bZT5b18m3ifCXLjD5PwSA77l732c4w_veKCyjTD7bS3xfYqOhjXhzDEVP6Ir18_YkxHnTM9P9YJ9-_jh683n6u7Lp9ubd3eVU6BK1fYGxt6Og-qVM470SG2jtAUU0FjjtAJDNJjaaWhki4oGsDViY0bb2h7VBXt9n7sd8WulXLrg8_FZXCiuuTOiMUYq9V9QWCuhlnoDL-9Bl2LOicZun3zAdOgEdEdb3dFW98_WBr88pa59oOEBPenZgFcnAPMmZky4OJ8fuFq3GrRUfwHaeaEW</recordid><startdate>20040301</startdate><enddate>20040301</enddate><creator>MOORE, Katrina H</creator><creator>THALER, Howard T</creator><creator>TAN, Lee K</creator><creator>BORGEN, Patrick I</creator><creator>CODY, Hiram S</creator><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20040301</creationdate><title>Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: Biologic metastasis or procedural artifact?</title><author>MOORE, Katrina H ; THALER, Howard T ; TAN, Lee K ; BORGEN, Patrick I ; CODY, Hiram S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c303t-8b70fb9fd3b3c7ce4fe863490a10697c4307eed75c40628a3ed095aa67f989ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Biopsy, Needle</topic><topic>Breast Neoplasms - pathology</topic><topic>Carcinoma - pathology</topic><topic>Carcinoma - secondary</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Logistic Models</topic><topic>Lymph Nodes - pathology</topic><topic>Lymphatic Metastasis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Invasiveness - pathology</topic><topic>Neoplasm Staging</topic><topic>Probability</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Registries</topic><topic>Sensitivity and Specificity</topic><topic>Sentinel Lymph Node Biopsy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MOORE, Katrina H</creatorcontrib><creatorcontrib>THALER, Howard T</creatorcontrib><creatorcontrib>TAN, Lee K</creatorcontrib><creatorcontrib>BORGEN, Patrick I</creatorcontrib><creatorcontrib>CODY, Hiram S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MOORE, Katrina H</au><au>THALER, Howard T</au><au>TAN, Lee K</au><au>BORGEN, Patrick I</au><au>CODY, Hiram S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: Biologic metastasis or procedural artifact?</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2004-03-01</date><risdate>2004</risdate><volume>100</volume><issue>5</issue><spage>929</spage><epage>934</epage><pages>929-934</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>Sentinel lymph node (SLN) biopsy is a new standard of care for patients with breast carcinoma, and allows enhanced pathologic analysis with serial sections and immunohistochemical (IHC) staining for cytokeratins to be performed on a routine basis. However, the significance of SLN micrometastases detected only by IHC is uncertain. Are these tumor cells truly markers of metastatic potential, or simply evidence of passive displacement by preoperative instrumentation of the tumor site? Here we evaluate whether the pattern of SLN metastasis in breast carcinoma is related to the degree of manipulation at biopsy before surgery, independently of other known predictors. Among 4016 consecutive eligible patients with breast carcinoma registered in a prospective SLN database at Memorial Sloan Kettering Cancer Center, we noted patient/tumor characteristics, pathologic status of the SLN (negative, positive by hematoxylin and eosin [H&amp;E], or positive only on IHC), and method of previous biopsy (none, fine-needle aspiration biopsy [FNAB], core needle biopsy, or surgical biopsy). Multivariate analysis showed that the likelihood of an H&amp;E-positive SLN was significantly associated with lymphovascular invasion, tumor size, tumor type, and tumor location, but not with the method of biopsy. In contrast, the likelihood of finding an SLN positive only on IHC was unassociated with any of the four variables above, but was significantly associated with the method of biopsy. After no previous biopsy, FNAB, core needle biopsy, or surgical biopsy, IHC-positive SLN were present in 1.2%, 3.0%, 3.8%, and 4.6% of patients, respectively (P = 0.002). These data suggest that the frequency of IHC-positive SLN in patients with breast carcinoma 1) is unrelated to conventional predictors of lymph node positivity, 2) is increased after instrumentation of the tumor site, and 3) is increased approximately proportionate to the degree of manipulation. A proportion of IHC-positive SLN were present before biopsy and therefore less likely to be artifactual.</abstract><cop>New York, NY</cop><pub>Wiley-Liss</pub><pmid>14983487</pmid><doi>10.1002/cncr.20035</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 2004-03, Vol.100 (5), p.929-934
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_71677233
source Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adult
Aged
Analysis of Variance
Biological and medical sciences
Biopsy, Needle
Breast Neoplasms - pathology
Carcinoma - pathology
Carcinoma - secondary
Female
Humans
Immunohistochemistry
Logistic Models
Lymph Nodes - pathology
Lymphatic Metastasis
Medical sciences
Middle Aged
Multivariate Analysis
Neoplasm Invasiveness - pathology
Neoplasm Staging
Probability
Prognosis
Prospective Studies
Registries
Sensitivity and Specificity
Sentinel Lymph Node Biopsy
Tumors
title Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: Biologic metastasis or procedural artifact?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T16%3A46%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunohistochemically%20detected%20tumor%20cells%20in%20the%20sentinel%20lymph%20nodes%20of%20patients%20with%20breast%20carcinoma:%20Biologic%20metastasis%20or%20procedural%20artifact?&rft.jtitle=Cancer&rft.au=MOORE,%20Katrina%20H&rft.date=2004-03-01&rft.volume=100&rft.issue=5&rft.spage=929&rft.epage=934&rft.pages=929-934&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.20035&rft_dat=%3Cproquest_cross%3E19920524%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19920524&rft_id=info:pmid/14983487&rfr_iscdi=true